Search

everythinglearnresearchcommunity

for

Search:↓

Baricitinib is effective and safe for long-term use in severe alopecia areata, improving hair regrowth and quality of life with few side effects.

Baricitinib showed mixed results in treating alopecia areata in children, with some improvement but also side effects.

Tofacitinib helps hair regrow in some kids with severe alopecia areata, but more research is needed on long-term effects.

The topical treatment WR 279,396 effectively healed cutaneous leishmaniasis in mice without relapse.

Dupilumab and ustekinumab are promising treatments for alopecia areata, showing significant hair regrowth.

Dupilumab can both improve and worsen alopecia areata, with higher IgE levels linked to better outcomes.

TPA is about 50 times more effective at promoting tumors than MZ.

A patient with multiple sclerosis developed skin reactions after Daclizumab treatment, requiring more data on the drug's effects.

Ablative fractional laser treatment nearly matches the gene reduction effects of topical vismodegib in skin cancer.

Patients with rheumatoid arthritis using tofacitinib had more serious side effects than those with alopecia areata.

Topical immunotherapy for alopecia areata may work by creating immune cell clusters in the skin.

New melanoma treatments can cause skin side effects, including skin cancer and rashes, but combining treatments may reduce these risks.

Ruxolitinib reduced inflammation and improved symptoms in APECED patients but may cause anemia and weight gain.

A patient with advanced kidney cancer and no hepatitis C developed skin inflammation due to a drug called interferon alpha-2a.

Biorregulatory therapy significantly improved the dog's health, reversing previous issues and eliminating the need for ongoing medication.

Baricitinib is effective in promoting hair growth in severe alopecia areata.

Chemical lumbar sympathectomy is an effective and safe treatment for idiopathic livedo reticularis.

A substance called miR-1246 may help treat severe hair loss by reducing certain immune cell activities.

A rare ovarian tumor was successfully treated with surgery and chemotherapy.

Baricitinib may effectively treat both alopecia areata and immune thrombocytopenia.

Blocking CD44 can reduce leukocyte migration in autoimmune skin diseases.

Tofacitinib helped a woman regrow her hair without relapses after other treatments failed.

Tofacitinib caused significant hair regrowth in adolescents with alopecia universalis who didn't respond to other treatments.

COVID-19 vaccination may trigger recurrence of cutaneous T-cell lymphoma in some patients.

The 308-nm excimer laser helps hair regrowth in some alopecia areata cases but not all.

The document concludes that the development of certain tumors is influenced by genetic background and that a specific gene modification can lead to tumor regression and reduced growth.

Combining Ficlatuzumab and Gefitinib can cause severe hair loss.

Baricitinib significantly regrows hair in teens with severe alopecia areata.

Sirolimus effectively reduces lesions and improves quality of life in Blue Rubber Bleb Nevus Syndrome with manageable side effects.